Literature DB >> 21199802

Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth.

Jo Waaler1, Ondrej Machon, Jens Peter von Kries, Steven Ray Wilson, Elsa Lundenes, Doris Wedlich, Dietmar Gradl, Jan Erik Paulsen, Olga Machonova, Jennifer L Dembinski, Huyen Dinh, Stefan Krauss.   

Abstract

Canonical Wnt signaling is deregulated in several types of human cancer where it plays a central role in tumor cell growth and progression. Here we report the identification of 2 new small molecules that specifically inhibit canonical Wnt pathway at the level of the destruction complex. Specificity was verified in various cellular reporter systems, a Xenopus double-axis formation assay and a gene expression profile analysis. In human colorectal cancer (CRC) cells, the new compounds JW67 and JW74 rapidly reduced active β-catenin with a subsequent downregulation of Wnt target genes, including AXIN2, SP5, and NKD1. Notably, AXIN2 protein levels were strongly increased after compound exposure. Long-term treatment with JW74 inhibited the growth of tumor cells in both a mouse xenograft model of CRC and in Apc(Min) mice (multiple intestinal neoplasia, Min). Our findings rationalize further preclinical and clinical evaluation of these new compounds as novel modalities for cancer treatment.
© 2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21199802     DOI: 10.1158/0008-5472.CAN-10-1282

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  77 in total

Review 1.  Development of anticancer agents targeting the Wnt/β-catenin signaling.

Authors:  Xiangqian Zhang; Jijun Hao
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

Review 2.  Small-molecule inhibitors of Wnt signaling pathway: towards novel anticancer therapeutics.

Authors:  Shilong Zheng; Jiawang Liu; Yanyuan Wu; Tien L Huang; Guangdi Wang
Journal:  Future Med Chem       Date:  2015-12-16       Impact factor: 3.808

Review 3.  Drugging Wnt signalling in cancer.

Authors:  Paul Polakis
Journal:  EMBO J       Date:  2012-05-22       Impact factor: 11.598

4.  MUC1-C drives MYC in multiple myeloma.

Authors:  Ashujit Tagde; Hasan Rajabi; Audrey Bouillez; Maroof Alam; Reddy Gali; Shannon Bailey; Yu-Tzu Tai; Teru Hideshima; Kenneth Anderson; David Avigan; Donald Kufe
Journal:  Blood       Date:  2016-02-23       Impact factor: 22.113

Review 5.  SP and KLF Transcription Factors in Digestive Physiology and Diseases.

Authors:  Chang-Kyung Kim; Ping He; Agnieszka B Bialkowska; Vincent W Yang
Journal:  Gastroenterology       Date:  2017-03-30       Impact factor: 22.682

Review 6.  LincRNa-p21: function and mechanism in cancer.

Authors:  Shaoyun Chen; Hairong Liang; Hui Yang; Kairu Zhou; Longmei Xu; Jiaxian Liu; Bei Lai; Li Song; Hao Luo; Jianming Peng; Zhidong Liu; Yongmei Xiao; Wen Chen; Huanwen Tang
Journal:  Med Oncol       Date:  2017-04-19       Impact factor: 3.064

7.  Tankyrase Sterile α Motif Domain Polymerization Is Required for Its Role in Wnt Signaling.

Authors:  Amanda A Riccio; Michael McCauley; Marie-France Langelier; John M Pascal
Journal:  Structure       Date:  2016-08-04       Impact factor: 5.006

8.  Small molecule modulators of Wnt/β-catenin signaling.

Authors:  Robert A Mook; Minyong Chen; Jiuyi Lu; Larry S Barak; H Kim Lyerly; Wei Chen
Journal:  Bioorg Med Chem Lett       Date:  2013-01-30       Impact factor: 2.823

Review 9.  Targeting Wnt signaling in colorectal cancer. A Review in the Theme: Cell Signaling: Proteins, Pathways and Mechanisms.

Authors:  Laura Novellasdemunt; Pedro Antas; Vivian S W Li
Journal:  Am J Physiol Cell Physiol       Date:  2015-08-19       Impact factor: 4.249

10.  Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with β-catenin (CTNNB1) status.

Authors:  Teppei Morikawa; Aya Kuchiba; Paul Lochhead; Reiko Nishihara; Mai Yamauchi; Yu Imamura; Xiaoyun Liao; Zhi Rong Qian; Kimmie Ng; Andrew T Chan; Jeffrey A Meyerhardt; Edward Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Cancer Res       Date:  2013-02-26       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.